Hochster Underscores Headway Made in Gastric/GEJ Cancers
December 16th 2021Dr. Hochster provides insight into the current gastric/GEJ landscape, spotlighting molecular testing approaches, the roles of chemoimmunotherapy combinations, ongoing research with biomarkers of response, and optimal treatment sequencing for patients with HER2-positive disease.
Read More
Shah and Wang Share Insights Into Optimized CAR T-Cell Therapy in Hematologic Malignancies
December 13th 2021Dr. Shah and Dr. Wang discuss the management of cytokine release syndrome and neurotoxicity, the referral process, and the need for academic and community collaboration for CAR T-cell therapy in hematologic malignancies.
Read More
Coombs Previews Anticipated ASH Abstracts in CLL
December 9th 2021Dr. Coombs discusses research that will be presented at the upcoming 2021 ASH Annual Meeting and Exposition in chronic lymphocytic leukemia, including that with covalent and noncovalent BTK inhibitors, COVID-19 vaccinations, and time-limited combinations.
Read More
Roychowdhury Relays Impact of Recent Infigratinib Approval in FGFR+ Cholangiocarcinoma
November 29th 2021Sameek Roychowdhury, MD, PhD, discusses the pivotal phase 2 trial with infigratinib in FGFR-positive cholangiocarcinoma, the safety and efficacy achieved with infigratinib, and the next steps for this agent.
Read More
Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC
November 18th 2021Dr. Kalyan and Dr. Mouli discuss the importance of multidisciplinary care in hepatocellular carcinoma, data regarding real-world personalization treatment recommendations, and the benefits of decision-making analysis tools in the space.
Read More
Ku Reviews Exciting ESMO Data in Gastric/GEJ Cancer
November 15th 2021Dr. Ku underscores key takeaways from the CheckMate649 and DESTINY-Gastric02 trials in gastric/GEJ cancer and highlights ongoing research that has the potential to further inform treatment selection and sequencing in the field
Read More
Gradishar Gives Insight Into the Growing Role of SERDs in Breast Cancer
November 11th 2021Dr. Gradishar discusses the evolution of SERDs in breast cancer, novel SERDs that could shift the paradigm of breast cancer treatment, and ongoing research that could solidify the role of these agents in the field.
Read More
OncLive® Honors 14 Cancer Care Pioneers With Giants Awards
November 10th 2021The 9th Annual Giants of Cancer Care® awards ceremony was a featured event at the 39th Annual CFS®: Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow®, hosted by Physicians’ Education Resource® LLC.
Read More
Tagawa Breaks Down FGFR Testing and the Use of Erdafitinib in Bladder Cancer
November 8th 2021Dr. Tagawa discusses the incidence and identification of FGFR alterations in bladder cancer, the approval and use of erdafitinib in the second-line setting for patients with advanced bladder cancer, and research directions with the FGFR inhibitor in the field.
Read More
FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL
November 1st 2021Dr. Shah discusses the FDA approval of brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia, key findings from the pivotal ZUMA-3 trial, and next steps with CAR T-cell therapy in the field.
Read More
Jain and Spaggiari Speak to Surgical and Systemic Considerations for CRC Liver Metastases
October 28th 2021Dr. Jain and Dr. Spaggiari highlight key advancements in the treatment of patients with colorectal cancer liver metastases, patient and disease factors to consider during surgical and systemic treatment decisions, and the importance of multidisciplinary care in this patient population.
Read More
Johnson Previews the Potential Utility of VS-6766 Plus Defactinib in KRAS+ NSCLC
October 25th 2021Dr. Johnson discusses the mechanism of action of VS-6766 alone and in combination with defactinib, expectations for the ongoing phase 2 RAMP 202 trial in KRAS-mutant non–small cell lung cancer, and where the combination could be used in practice pending further positive study results.
Read More
Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients
October 21st 2021Dr. Abid discusses immune-compromising factors that are indigenous to CAR T-cell therapy recipients, the immunogenic potential of different COVID-19 vaccines, determinants of vaccine responses, and the potential need for booster vaccine dosing in this population.
Read More
Ilson Delves Into the Development of Checkpoint Inhibition in Gastric/GEJ Cancers
October 18th 2021Dr. Ilson discusses treatment sequencing for patients with gastric and gastroesophageal junction cancer, the integration of immunotherapy into the frontline setting, and key ongoing studies in the field.
Read More
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
October 11th 2021Dr. DeNunzio discusses how proton beam therapy is being used throughout oncology, the advantages of the modality and how it complements other treatment interventions, and where research with the therapy is headed.
Read More
Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer
October 7th 2021Dr. Moore discusses the basis for studying the combination of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer, data that has been generated with the combination from the phase 1/2 FRAME trial, and the potential role for the combination in clinical practice.
Read More
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
October 4th 2021Dr. Patel discusses the role of biomarker testing in lung cancer, the FDA approvals of amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC, and future research directions in this subset of lung cancer.
Read More
Genomically Guided Radiation Dosing in Oncology: Ready for Prime Time?
September 30th 2021Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation therapy in solid tumors and what using genomics to guide radiation dosing decisions could mean for oncology practices.
Read More
Aggarwal and Girard Analyze Data Amassed With Durvalumab in Unresectable Stage III NSCLC
September 27th 2021Dr. Aggarwal and Dr. Girard discuss the significance of the 5-year survival data from the pivotal PACIFIC trial and the real-world benefit of the study regimen in patients with unresectable stage III non–small cell lung cancer.
Read More
Updates and Advances in the Treatment of Metastatic HER2+ Breast Cancer
September 14th 2021Dr Pegram and colleagues focus on key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.
Read More